TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6781657

Group type: EXPERIMENTAL
Intervention: Inhaled verapamil (estimated dose 3 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (estimated dose 12 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 29788198

Group type: EXPERIMENTAL
Intervention: VTE chemoprophylaxis initiated in 412 patients (82.4%)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: VTE chemoprophylaxis initiated before VTE diagnosis in 401 patients (80.2%)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Infection within 30 days
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Starting VTE chemoprophylaxis after 72 hours
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: VTE chemoprophylaxis in IVH
Number of subjects: 500
Study: 27232556

Group type: EXPERIMENTAL
Intervention: Stepping exercise group (SG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study: 25873132

Group type: EXPERIMENTAL
Intervention: Pasireotide (long-acting release, 60 mg injection)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 34
Study: 23347140

Group type: EXPERIMENTAL
Intervention: Computed tomography pulmonary angiography scan (CT-scan)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Perfusion scintigraphy scan (Q-scan)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Enoxaparin with vitamin K antagonist (VKA)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 347
Study: 21414740

Group type: EXPERIMENTAL
Intervention: FOLFOX4 regimen (oxaliplatin 85 mg/m(2) as a 2‐h infusion on day 1, leucovorin 200 mg/m(2)/d, 5‐fluorouracil 400 mg/m(2)/d bolus and 600 mg/m(2)/d infusion for 2 consecutive days every 2 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: LV5Fu2 regimen (leucovorin 200 mg/m(2)/d, 5‐fluorouracil 400 mg/m(2)/d bolus and 600 mg/m(2)/d infusion for 2 consecutive days every 2 weeks)
Number of subjects: 80
Study: 19707146

Group type: EXPERIMENTAL
Intervention: Ultrasonographic measurement of antral area after 12 h fasting
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultrasonographic measurement of antral area 2 h after ingestion of 200 ml of nonclear liquids
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultrasonographic measurement of antral area 2 h after a solid meal of 300 kcal
Number of subjects: 22
Study: 17689023

Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy, 1,000 mg/m2 twice daily for 2 weeks, followed by capecitabine (650-1,000 mg/m2 orally twice daily 5 days/week) combined with radiotherapy for 5 weeks.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Capecitabine-based chemoradiotherapy
Number of subjects: 66
Study: 15279529

Group type: EXPERIMENTAL
Intervention: 2 sessions of motivational enhancement therapy (MET)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 9 sessions of multicomponent therapy (including MET, cognitive-behavioral therapy, and case management)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Delayed treatment control (DTC)
Number of subjects: 450
Study: 11568588

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) treatment, 600 mg in 4 mL saline per day, administered via nasal aerosol in five 2-minute sessions every 3 or 4 waking hours for 2 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (4 mL saline per day), administered via nasal aerosol in the same manner as GSH treatment.
Number of subjects: 60
Study: 10705020

Group type: EXPERIMENTAL
Intervention: Single 8 Gy fraction
Number of subjects: 90

Group type: COMPARATOR
Intervention: 20 Gy in 5 fractions
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both arms combined
Number of subjects: 90
Study: 9272770

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (L-CHO)
Number of subjects: 8
Study: 1279497

Group type: EXPERIMENTAL
Intervention: 500 mg flutamide for three months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 750 mg flutamide for three months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both doses (500 mg and 750 mg)
Number of subjects: 23
Study: 2870833

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 10
Study: 29885369

Group type: EXPERIMENTAL
Intervention: Endocannabinoidome lipid mediators (AEA, OEA, PEA, SEA, 2-AG)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Endocannabinoidome lipid mediators (2-AG)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Endocannabinoidome lipid mediators (AEA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Healthy control subjects (N=116)
Number of subjects: 104
Study: 27091583

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 24717147

Group type: EXPERIMENTAL
Intervention: Diode Laser (DL) pulpotomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Formocresol (FC) pulpotomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ferric Sulphate (FS) pulpotomy
Number of subjects: 120
Study: 22696517

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conservative therapy (pharmacological)
Number of subjects: 52
Study: 20386884

Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxycodone 40 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg + 0.0001 mg NTX
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg + 0.001 mg NTX
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxycodone 40 mg + 0.0001 mg NTX
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxycodone 40 mg + 0.001 mg NTX
Number of subjects: 14
Study: 18541560

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified seasoning powder (5 mg Fe, 5 mg Zn, 50 mug I, 270 mug vitamin A per serving) consumed with school lunch 5 days/week
Number of subjects: 569

Group type: COMPARATOR
Intervention: Control group (no fortification)
Number of subjects: 569
Study: 15741775

Group type: EXPERIMENTAL
Intervention: Formoterol 5 microg via Certihaler
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Formoterol 10 microg via Certihaler
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Formoterol 15 microg via Certihaler
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Formoterol 30 microg via Certihaler
Number of subjects: 77

Group type: COMPARATOR
Intervention: Formoterol 12 microg via Aerolizer
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 11921451

Group type: EXPERIMENTAL
Intervention: Maternal history of asthma
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Sensitization to house dust mites
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Sensitization to Alternaria
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Skin test reactivity (STR) to house dust mite
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Skin test reactivity (STR) to cat dander
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Maternal history of eczema
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Skin test reactivity (STR) to dog dander
Number of subjects: 208

Group type: COMPARATOR
Intervention: Current wheezing
Number of subjects: 208
Study: 10444434

Group type: EXPERIMENTAL
Intervention: T(3) (50 micrograms per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7483181

Group type: EXPERIMENTAL
Intervention: Medical strategies with low to moderate doses of medication titrated over 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revascularization strategies
Number of subjects: 0
Study: 2033109

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30134739

Group type: EXPERIMENTAL
Intervention: Partial rebreathing device
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 11
Study: 27229348

Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Melatonin 10 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Switch from melatonin to agomelatine
Number of subjects: 24
Study: 24612998

Group type: EXPERIMENTAL
Intervention: Home-based treadmill training (14 weeks, 3 sessions per week, 40 min at 55-70% peak heart rate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Home-based treadmill training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 60
Study: 22483162

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 20499349

Group type: EXPERIMENTAL
Intervention: 5 mg of zoledronate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18949107

Group type: EXPERIMENTAL
Intervention: Sputum strategy (SS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Clinical strategy (CS)
Number of subjects: 39
Study: 15721729

Group type: EXPERIMENTAL
Intervention: Constant positive airway pressure (12 ± 2 cm H(2)O)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pressure support (3.1 ± 0.3 cm H(2)O)
Number of subjects: 9
Study: 12755522

Group type: EXPERIMENTAL
Intervention: Diagnosis by Behvarzes
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Diagnosis by specialists (obstetricians)
Number of subjects: 2000
Study: 11011338

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (1 to 4 mg/d)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin treatment
Number of subjects: 80
Study: 8803378

Group type: EXPERIMENTAL
Intervention: Sustained-release morphine (SRM) administered at a 12‐hr interval
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sustained-release morphine (SRM)
Number of subjects: 44
Study: 1454315

Group type: EXPERIMENTAL
Intervention: Timolol 0.25% or 0.5% twice daily
Number of subjects: 189

Group type: COMPARATOR
Intervention: Pilocarpine 2% or 4% four times daily
Number of subjects: 189
Study: 6609521

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (Abboticin) in standard dosage for the last 10 days before surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (Abboticin)
Number of subjects: 75
Study: 31579048

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 414

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Nomograms based on clinicopathologic factors
Number of subjects: 414
Study: 28506134

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg BIW
Number of subjects: 307

Group type: COMPARATOR
Intervention: Etanercept (ETN) 50 mg QW
Number of subjects: 307
Study: 26883052

Group type: EXPERIMENTAL
Intervention: Plan-It Commander (serious game intervention)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 170
Study: 24429167

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Etanercept alone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Combination of MTX and etanercept
Number of subjects: 29
Study: 21988494

Group type: EXPERIMENTAL
Intervention: Ciclosporin (CsA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 10
Study: 20651609

Group type: EXPERIMENTAL
Intervention: Homozygous variant genotypes for SLC19A1 IVS4(2117) C>T, IVS5(9148) C>A, and wild-type genotype for exon6(2522) C>T
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Heterozygous TC genotype for GGH IVS5(1042) T>C
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Heterozygous (GA) for the FPGS IVS1 (28) G>A polymorphism
Number of subjects: 54
Study: 17365851

Group type: EXPERIMENTAL
Intervention: Garlic oil (9.9 g dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16305652

Group type: EXPERIMENTAL
Intervention: rHuEpo administration for 6 months
Number of subjects: 30
Study: 11889776

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Droperidol 5.0 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Epidural administration of 0.25% bupivacaine 40 ml and buprenorphine 0.4 mg
Number of subjects: 78
Study: 10391959

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Salmeterol + Salbutamol
Number of subjects: 14
Study: 7616870

Group type: EXPERIMENTAL
Intervention: Combined norethisterone acetate (NETA)/oestradiol (E2)‐TTS, delivering 0.25 mg NETA and 50 micrograms E2 per day, continuously for 12 calendar months
Number of subjects: 50
Study: 1967425

Group type: EXPERIMENTAL
Intervention: Soluble prednisolone (20 mg twice daily on days 1-10 of the female partner's menstrual cycle, followed by 5 mg on days 11 and 12)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Soluble prednisolone
Number of subjects: 43
Study: 326101

Group type: EXPERIMENTAL
Intervention: Flunisolide aerosol administered every 12 hours for eight weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31323067

Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (ML)
Number of subjects: 51
Study: 28363933

Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg and 0.5 mg)
Number of subjects: 69
Study: 25480607

Group type: EXPERIMENTAL
Intervention: Closed mesenteric defect
Number of subjects: 105

Group type: COMPARATOR
Intervention: Open mesenteric defect
Number of subjects: 105
Study: 22835606

Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI) with powdered pasteurised egg, starting with 1mg and increasing weekly to 10g over an average duration of 10 weeks.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Elimination diet (control group).
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Skin prick tests with powdered egg at various dilutions after SOTI.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: IgG levels with egg white after SOTI.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Specific IgE concentration after SOTI.
Number of subjects: 72
Study: 21486886

Group type: EXPERIMENTAL
Intervention: User Centred Design format
Number of subjects: 27

Group type: COMPARATOR
Intervention: Paper format
Number of subjects: 27

Group type: COMPARATOR
Intervention: CPOE Test format
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: All formats
Number of subjects: 27
Study: 19925284

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg for six months (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 30
Study: 16797162

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 12826964

Group type: EXPERIMENTAL
Intervention: remifentanil/propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: isoflurane/fentanyl
Number of subjects: 60
Study: 10474065

Group type: EXPERIMENTAL
Intervention: Org 4428 (25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Org 4428 (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8683634

Group type: EXPERIMENTAL
Intervention: Combined adjuvant chemotherapy and radiation therapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Adjuvant radiation therapy alone
Number of subjects: 204
Study: 1718154

Group type: EXPERIMENTAL
Intervention: Mepartricin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 6822108

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 to 30 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29669001

Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine 10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine 13
Number of subjects: 0
Study: 28229515

Group type: EXPERIMENTAL
Intervention: Individual therapy sessions
Number of subjects: 13

Group type: COMPARATOR
Intervention: Group therapy sessions
Number of subjects: 13
Study: 27033905

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 1 mg/kg IV (group DK)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methadone 0.2 mg/kg IV (group M)
Number of subjects: 32
Study: 25026506

Group type: EXPERIMENTAL
Intervention: Serum osteoprotegerin (OPG) levels measured at randomization.
Number of subjects: 4063
Study: 21708439

Group type: EXPERIMENTAL
Intervention: 500 mgI/kg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 600 mgI/kg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 630 mgI/kg or more
Number of subjects: 103

Group type: COMPARATOR
Intervention: 700 mgI/kg
Number of subjects: 103
Study: 19720956

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 17907488

Group type: EXPERIMENTAL
Intervention: External bleaching with 10% carbamide peroxide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: External bleaching with 35% hydrogen peroxide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Internal/external bleaching with 35% hydrogen peroxide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intracoronal bleaching with a paste of sodium perborate mixed with 9% hydrogen peroxide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 30
Study: 14720266

Group type: EXPERIMENTAL
Intervention: TBC1269 (30 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11223496

Group type: EXPERIMENTAL
Intervention: ProBAN sublingual tablets and nicotine gum
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo tablets and nicotine gum
Number of subjects: 80
Study: 10208287

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (CMI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (DMI)
Number of subjects: 17
Study: 7887003

Group type: EXPERIMENTAL
Intervention: Glenohumeral ligaments
Number of subjects: 8
Study: 2789749

Group type: EXPERIMENTAL
Intervention: Tutor-guided training
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Self-guided training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 1088099

Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline on admission and 100 mg on the second day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline on admission only
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 300 mg of doxycycline on admission only
Number of subjects: 4

Group type: COMPARATOR
Intervention: 500 mg of tetracycline every 6 h for 48 h
Number of subjects: 4
Study: 31925529

Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy after 1-month ticagrelor and aspirin dual anti-platelet therapy (DAPT)
Number of subjects: 2171

Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin
Number of subjects: 2171
Study: 30477810

Group type: EXPERIMENTAL
Intervention: Intervention group (targeted screening)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (opportunistic screening)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Standard invitation letter
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Enhanced invitation letter
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hospital-based care
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Community care
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of intervention
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 58
Study: 28685712

Group type: EXPERIMENTAL
Intervention: Shensong Yangxin capsules (SSYX)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study: 26076182

Group type: EXPERIMENTAL
Intervention: Remote Internet follow-up for 6 months after discharge
Number of subjects: 128

Group type: COMPARATOR
Intervention: Routine outpatient follow-up
Number of subjects: 128
Study: 23307069

Group type: EXPERIMENTAL
Intervention: 32 mg of CBD administered post-extinction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 32 mg of CBD administered before extinction
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 48
Study: 21708803

Group type: EXPERIMENTAL
Intervention: Evening media use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daytime media use with violent content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bedroom television presence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonviolent daytime media use
Number of subjects: 0
Study: 19165663

Group type: EXPERIMENTAL
Intervention: 750 IU of hCG every three days during endometrial preparation with estradiol
Number of subjects: 22

Group type: COMPARATOR
Intervention: No hCG during endometrial priming with estradiol
Number of subjects: 22
Study: 16500921

Group type: EXPERIMENTAL
Intervention: Propranolol infusion with mixed liquid meal (700 kcal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no propranolol) with mixed liquid meal (700 kcal)
Number of subjects: 12
Study: 14985214

Group type: EXPERIMENTAL
Intervention: Enteral glutamine (0.6 g.kg(‐1).d(‐1))
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Enteral glycine (isonitrogenous amounts)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (unsupplemented formula)
Number of subjects: 26